title: Antifibrinolytic agents in subarachnoid haemorrhage.
abstract: For many years clinicians have used antifibrinolytic agents to try to reduce rebleeding after subarachnoid haemorrhage. Early studies of their effectiveness produced conflicting results. This paper re-evaluates the available trials and considers benefits in the light of potential complications. Present evidence conclusively demonstrates that epsilon-aminocaproic acid and tranexamic acid administered in standard dosage, reduce the risk of rebleeding but, as a result of an increased incidence of ischaemic complications, do not benefit patients' outcome.
mesh_terms: D000933:Antifibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D013345:Subarachnoid Hemorrhage / Q000188:drug therapy*
chemical_list: D000933:Antifibrinolytic Agents